药物洗脱球囊导管市场机会、成长动力、产业趋势分析与预测 2025 - 2034

2024 年，全球药物洗脱球囊导管市场价值为6.378 亿美元，预计2025 年至2034 年复合年增长率为9.9%。对药物洗脱球囊导管的偏好不断增加。

冠状动脉疾病、中风和周边动脉疾病（PAD）等心血管疾病（CVD）已成为全球健康问题。影响因素包括不健康的生活方式、人口老化以及高血压和糖尿病等疾病的普遍发生。这些因素导致对微创手术的需求激增，DEB 导管成为治疗动脉阻塞和增强血流且无需永久性植入物的首选解决方案。

DEB 导管，也称为药物涂层球囊，在球囊扩张过程中将紫杉醇或西罗莫司等抗增殖药物直接输送到动脉壁。这种受控药物释放有助于治疗增生并改善週边血管和冠状血管疾病的结果。市场依产品分为冠状动脉疾病和周围血管疾病 DEB 导管。 2024年，週边血管疾病领域引领市场，创造了3.53亿美元的收入。

週边血管疾病 DEB 导管对于支架可能不适合的复杂病变特别有效。透过减少平滑肌细胞增生和防止再狭窄，这些导管可维持最佳血流并改善患者预后。由于恢復时间较短且併发症较少，人们对微创介入的偏好不断增加，这极大地促进了 DEB 导管在周边血管应用中的普及。

从材料来看，市场分为聚氨酯、尼龙和其他材料。基于聚氨酯的DEB 导管在2024 年产生2.254 亿美元的收入，预计到2034 年将以10.4% 的复合年增长率增长。的血管结构中导航，确保患者舒适度，并降低手术过程中受伤的风险。

由于心血管和周边动脉疾病入院人数增加，到 2024 年，医院和诊所将占据最大的市场份额。由于对先进外科护理和微创干预的需求不断增长，预计到 2034 年，该细分市场将达到 9.383 亿美元。

就地区表现而言，北美地区在2024 年以2.722 亿美元的收入占据市场主导地位。 这一增长归因于该地区先进的医疗基础设施、CVD 的高患病率以及DEB 技术在介入性心臟病学和血管护理领域的广泛采用。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 週边疾病和心血管疾病的盛行率不断上升
    • 药物洗脱球囊导管的技术进步
    • 对微创手术的偏好日益增加
    • 老年人口不断增加
  • 产业陷阱与挑战
    • 产品成本高
    • 使用药物洗脱球囊导管相关的感染风险
• 成长潜力分析
• 监管环境
• 报销场景
• 技术景观
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2034 年

• 主要趋势
• 冠状动脉疾病药物洗脱球囊导管
  • 紫杉醇
  • 西罗莫司
• 週边血管疾病药物洗脱球囊导管
  • 紫杉醇
  • 西罗莫司

第 6 章：市场估计与预测：按材料划分，2021 - 2034 年

• 主要趋势
• 聚氨酯
• 尼龙
• 其他材料

第 7 章：市场估计与预测：按最终用途，2021 - 2034 年

• 主要趋势
• 医院和诊所
• 门诊手术中心
• 导尿实验室

第 8 章：市场估计与预测：按地区划分，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 9 章：公司简介

• Aachen Resonance GmbH
• B. Braun
• Becton, Dickinson and Company
• Biosensors International
• Biotronik AG
• Boston Scientific Corporation
• Eurocor GmbH
• iVascular SLU
• Zhejiang Barty Medical Technology Co.Ltd
• Lepu Medical Technology(Beijing) Co. Ltd.
• MedAlliance
• Medtronic plc

The Global Drug-Eluting Balloon Catheters Market was valued at USD 637.8 million in 2024 and is projected to grow at a CAGR of 9.9% from 2025 to 2034. This expansion is primarily driven by the rising prevalence of peripheral and cardiovascular diseases, increasing preference for minimally invasive treatments, and the growing aging population worldwide.

Cardiovascular diseases (CVDs) such as coronary artery disease, strokes, and peripheral artery disease (PAD) have become a global health concern. Contributing factors include unhealthy lifestyles, aging populations, and the widespread occurrence of conditions like hypertension and diabetes. These factors have led to a surge in demand for minimally invasive procedures, with DEB catheters emerging as a preferred solution for managing arterial blockages and enhancing blood flow without the need for permanent implants.

DEB catheters, also known as drug-coated balloons, deliver antiproliferative drugs such as paclitaxel or sirolimus directly to the arterial walls during balloon expansion. This controlled drug release helps treat hyperplasia and improve outcomes in both peripheral and coronary vascular diseases. The market is segmented by product into coronary artery disease and peripheral vascular disease DEB catheters. In 2024, the peripheral vascular disease segment led the market, generating USD 353 million in revenue.

Peripheral vascular disease DEB catheters are particularly effective for complex lesions where stents may not be suitable. By reducing smooth muscle cell proliferation and preventing restenosis, these catheters maintain optimal blood flow and improve patient outcomes. The rising preference for minimally invasive interventions due to shorter recovery times and fewer complications has significantly contributed to the popularity of DEB catheters for peripheral vascular applications.

Material-wise, the market is categorized into polyurethane, nylon, and other materials. Polyurethane-based DEB catheters generated USD 225.4 million in revenue in 2024 and are expected to grow at a CAGR of 10.4% through 2034. Known for its flexibility, biocompatibility, and durability, polyurethane is ideal for navigating complex vascular structures, ensuring patient comfort, and reducing the risk of injury during procedures.

Hospitals and clinics accounted for the largest share of the market in 2024, driven by increasing admissions for cardiovascular and peripheral artery disorders. The segment is expected to reach USD 938.3 million by 2034, supported by the growing demand for advanced surgical care and minimally invasive interventions.

In terms of regional performance, North America dominated the market with USD 272.2 million in revenue in 2024. This growth is attributed to the region's advanced healthcare infrastructure, high prevalence of CVDs, and widespread adoption of DEB technology in interventional cardiology and vascular care.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of peripheral and cardiovascular diseases
    • 3.2.1.2 Technological advancements in drug-eluting balloon catheters
    • 3.2.1.3 Increasing preference for minimally invasive procedures
    • 3.2.1.4 Rising geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of product
    • 3.2.2.2 Risk of infection associated with the use of drug-eluting balloon catheters
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technology landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Coronary artery disease drug-eluting balloon catheters
  • 5.2.1 Paclitaxel
  • 5.2.2 Sirolimus
• 5.3 Peripheral vascular disease drug-eluting balloon catheters
  • 5.3.1 Paclitaxel
  • 5.3.2 Sirolimus

Chapter 6 Market Estimates and Forecast, By Material, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Polyurethane
• 6.3 Nylon
• 6.4 Other materials

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Ambulatory surgical centers
• 7.4 Catheterization laboratories

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Aachen Resonance GmbH
• 9.2 B. Braun
• 9.3 Becton, Dickinson and Company
• 9.4 Biosensors International
• 9.5 Biotronik AG
• 9.6 Boston Scientific Corporation
• 9.7 Eurocor GmbH
• 9.8 iVascular S.L.U.
• 9.9 Zhejiang Barty Medical Technology Co.Ltd
• 9.10 Lepu Medical Technology(Beijing) Co. Ltd.
• 9.11 MedAlliance
• 9.12 Medtronic plc